The long-term tolerability of bencyclane ('Fludilat') in patients with peripheral occlusive disease: a 48-week prospective double-blind controlled study versus placebo.
In a controlled, multi-centre, double-blind trial, 75 patients with Stage II peripheral occlusive disease (Fontaine IIa) were treated with either 200 mg bencyclane twice daily or placebo over a period of 12 months. Undesired drug effects and concomitant phenomena were documented, and efficacy was evaluated. Bencyclane caused a slight, clinically negligible decrease in blood pressure. The pulse rate remained mostly unchanged, ECG and laboratory parameters showed no changes which would indicate a specific effect of the test substance. In the context of the generally low incidence of concomitant effects, patients in the bencyclane group mentioned symptoms such as insomnia, depressive mood, sweating and reduced motoricity more often than those in the placebo group. These symptoms are regarded as signs of the central nervous actions of the drug. The parameters used to assess the efficacy, i.e. the pain-free walking distance estimated by the patients and the physician's global judgment based on Ratschow's test, the palpability of the pedal pulse, the walking range and the patients' subjective statements about the incidence of chill, formication, and pain in the legs, showed a constant and statistically significant superiority of bencyclane over placebo.
Herrmann
W M
WM
AFB Institut für Arzneimittelforschung GmbH, Berlin, Germany.
Schärer
E
E
D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001537:Bencyclane / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003258:Consumer Behavior; D004311:Double-Blind Method; D006801:Humans; D011446:Prospective Studies; D011674:Pulse; D013997:Time Factors; D016138:Walking
D001537:Bencyclane